AIM: To investigate the association between TP53 Arg72Pro polymorphism and esophageal cancer (EC) risk using meta-analysis. METHODS: All eligible studies published before March 1, 2010 were selected by searching PubMed using keywords "p53" or "TP53", "polymorphism" or "variation", "esophageal" and "cancer" or "carcinoma". Crude odds ratios (ORs) with 95% confidence intervals (CIs) were assessed for EC risk associated with TP53 Arg72Pro polymorphism using fixed- and random-effects models. RESULTS: Nine case-control studies involving 5545 subjects were included in this meta-analysis. Significantly reduced risk of EC was associated with TP53 genotypes for Arg/Arg + Arg/Pro vs Pro/Pro (OR = 0.73, 95% CI: 0.57-0.94, P = 0.014). Subgroup analyses according to the source of controls and the specimens used for determining TP53 Arg72Pro genotypes or sample size showed that significantly reduced risk was observed only in studies which have population-based controls (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.66, P < 0.001), and use white blood cells or normal tissue to assess TP53 genotypes of cases (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.65, P < 0.001) or include at least 200 subjects (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.65, P < 0.001). Analysis restricted to well-designed studies also supported the significantly decreased risk of EC (Arg/Arg vs Pro/Pro: OR = 0.54, 95% CI: 0.46-0.64, P < 0.001). CONCLUSION: TP53 Arg72 carriers are significantly associated with decreased EC risk. Nevertheless, more well-designed studies are needed to confirm our findings.
AIM: To investigate the association between TP53Arg72Pro polymorphism and esophageal cancer (EC) risk using meta-analysis. METHODS: All eligible studies published before March 1, 2010 were selected by searching PubMed using keywords "p53" or "TP53", "polymorphism" or "variation", "esophageal" and "cancer" or "carcinoma". Crude odds ratios (ORs) with 95% confidence intervals (CIs) were assessed for EC risk associated with TP53Arg72Pro polymorphism using fixed- and random-effects models. RESULTS: Nine case-control studies involving 5545 subjects were included in this meta-analysis. Significantly reduced risk of EC was associated with TP53 genotypes for Arg/Arg + Arg/Pro vs Pro/Pro (OR = 0.73, 95% CI: 0.57-0.94, P = 0.014). Subgroup analyses according to the source of controls and the specimens used for determining TP53Arg72Pro genotypes or sample size showed that significantly reduced risk was observed only in studies which have population-based controls (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.66, P < 0.001), and use white blood cells or normal tissue to assess TP53 genotypes of cases (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.65, P < 0.001) or include at least 200 subjects (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.65, P < 0.001). Analysis restricted to well-designed studies also supported the significantly decreased risk of EC (Arg/Arg vs Pro/Pro: OR = 0.54, 95% CI: 0.46-0.64, P < 0.001). CONCLUSION:TP53Arg72 carriers are significantly associated with decreased EC risk. Nevertheless, more well-designed studies are needed to confirm our findings.
Authors: A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks Journal: Nature Date: 1998-05-21 Impact factor: 49.962
Authors: Huda A Eltahir; Ameera A M Adam; Zeinab A Yahia; Noon F Ali; Dalia M Mursi; Ashraaf M Higazi; Nahid A Eid; Ahmed M Elhassan; Hiba S Mohammed; Muntaser E Ibrahim Journal: Mol Biol Rep Date: 2012-10-08 Impact factor: 2.316
Authors: Helena S Thurow; Ricardo Haack; Fernando P Hartwig; Isabel O De Oliveira; Odir A Dellagostin; Denise P Gigante; Bernardo L Horta; Tiago Collares; Fabiana K Seixas Journal: J Biosci Date: 2011-12 Impact factor: 1.826
Authors: Leyla B Djansugurova; Anastassiya V Perfilyeva; Gulnur S Zhunusova; Kira B Djantaeva; Olzhas A Iksan; Elmira M Khussainova Journal: Front Genet Date: 2013-05-02 Impact factor: 4.599